Cantitate/Preț
Produs

Multiple Sclerosis Therapeutics

Editat de Jeffrey A. Cohen, Richard A. Rudick
en Limba Engleză Hardback – 19 oct 2011
This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors.
Citește tot Restrânge

Preț: 166620 lei

Preț vechi: 175390 lei
-5% Nou

Puncte Express: 2499

Preț estimativ în valută:
31891 33238$ 26548£

Carte disponibilă

Livrare economică 16-30 decembrie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780521766272
ISBN-10: 0521766273
Pagini: 770
Ilustrații: 150 b/w illus. 29 colour illus.
Dimensiuni: 225 x 282 x 41 mm
Greutate: 2.38 kg
Ediția:4th edition.
Editura: Cambridge University Press
Colecția Cambridge University Press
Locul publicării:Cambridge, United Kingdom

Cuprins

Part I. Introduction; Part II. Clinical Trial Methodology; Part III. Clinical Trials of Multiple Sclerosis Therapies; Part IV. Therapy in Clinical Practice.

Descriere

An indispensable reference for researchers, research sponsors and neurologists interested in the rapidly developing field of multiple sclerosis therapeutics.